Medications That Improve Survival in HFrEF
An ACE inhibitor (or ARB) combined with a beta-blocker forms the foundational therapy that improves survival in this patient with heart failure and reduced ejection fraction (EF 30%). Both medications carry Class I, Level A recommendations and should be initiated together as first-line therapy 1.
Core Survival-Improving Medications
The evidence-based pharmacotherapy for HFrEF consists of four medication classes that have demonstrated mortality reduction:
1. ACE Inhibitors (First-Line)
- Reduce mortality by 13-16% in symptomatic HFrEF 2
- Class I, Level A recommendation for all symptomatic patients 1
- Proven to reduce HF hospitalization and death when combined with beta-blockers
- Start low (e.g., enalapril 2.5 mg twice daily) and titrate to target doses (enalapril 10-20 mg twice daily) 2
2. Beta-Blockers (First-Line, Co-Equal Priority)
- Reduce mortality by 38 events per 1000 patient-years 2
- Class I, Level A recommendation 1
- Only three beta-blockers proven effective: bisoprolol, carvedilol, or metoprolol succinate 2
- Must be initiated in stable patients (not during acute decompensation)
- Start low (e.g., carvedilol 3.125 mg twice daily) and uptitrate to target doses (carvedilol 25-50 mg twice daily) 2
3. Mineralocorticoid Receptor Antagonists (MRA)
- Reduce mortality by 57 events per 1000 patient-years 2
- Class I, Level A recommendation for patients remaining symptomatic despite ACE-I and beta-blocker 1
- Spironolactone or eplerenone
- Add as third agent if symptoms persist on dual therapy
4. Sacubitril/Valsartan (ARNI)
- Provides ≥20% mortality reduction compared to ACE inhibitors 3
- Class I, Level B recommendation as replacement for ACE-I in patients remaining symptomatic on optimal therapy 1
- Superior to ACE inhibitors for reducing sudden death 3
- Should replace ACE-I (not add to it) in ambulatory patients on ACE-I + beta-blocker + MRA
Algorithmic Approach for This Patient
Step 1: Initiate ACE inhibitor (or ARB if ACE-I intolerant) at low dose
- Monitor BP, renal function, potassium at 1-2 weeks
- Uptitrate every 2 weeks to target dose
Step 2: Initiate beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) once stable
- Start low dose
- Uptitrate every 2 weeks to target dose
- Do NOT start during acute decompensation
Step 3: Add MRA if symptomatic despite ACE-I + beta-blocker
- Monitor potassium and renal function closely
- Avoid if creatinine >2.5 mg/dL or K+ >5.0 mmol/L 2
Step 4: Consider switching ACE-I to sacubitril/valsartan if remains symptomatic on triple therapy
- Requires 36-hour washout from ACE-I
- Provides additional mortality benefit 1
Step 5: Add SGLT2 inhibitor (emerging Class I recommendation) 4
Additional Considerations
Diuretics for Symptom Relief
- Class I, Level B recommendation for congestion (dyspnea, edema) 1
- Improve symptoms and exercise capacity but no proven mortality benefit
- Essential for this patient given progressive dyspnea and edema
- Always combine with ACE-I and beta-blocker 5
Critical Pitfalls to Avoid
- Do NOT use diltiazem or verapamil (Class III recommendation—increases HF worsening) 1
- Do NOT combine ARB + ACE-I + MRA (increased renal dysfunction and hyperkalemia risk) 1
- Do NOT delay beta-blocker initiation waiting for "perfect" ACE-I titration—both should be started early 2
- Do NOT maintain patients on starting doses indefinitely—forced uptitration to target doses is essential for mortality benefit 3
Nuances in the Evidence
While the 2016 ESC guidelines 1 provide the framework, more recent analyses 3 emphasize that neprilysin inhibitors, beta-blockers, and MRAs each provide ≥20% mortality reduction, while ACE inhibitors alone provide only 5-16% reduction. However, ACE inhibitors remain foundational as they were the first proven therapy and enable safe initiation of other agents.
The magnitude of benefit is substantial: treating 1000 patients for one year prevents 99 hospitalizations with ACE-I, 65 with beta-blockers, and 138 with spironolactone 2.